Pure Global
NCT06340750

BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

A Phase I Study of BAFF CAR-T Cells (LMY-920) for Treatment of Systemic Lupus Erythematosus
Luminary Therapeutics·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
LMY-920
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Luminary Therapeutics
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
Apr 15, 2026
Enrollment
18 participants
Primary outcome

Safety of the Treatment,Recommended Phase 2 Dose (RP2D)

Summary

This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of
 BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus
 erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve
 SLE disease activity scores.

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06340750
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06340750 through Pure Global AI's free database. This Phase 1 trial is sponsored by Luminary Therapeutics and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.